Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
House Dust Mite Allergy Overview 6
Therapeutics Development 7
Pipeline Products for House Dust Mite Allergy-Overview 7
Pipeline Products for House Dust Mite Allergy-Comparative Analysis 8
House Dust Mite Allergy-Therapeutics under Development by Companies 9
House Dust Mite Allergy-Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
House Dust Mite Allergy-Products under Development by Companies 13
House Dust Mite Allergy-Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Anergis SA 15
Biomay AG 16
Circassia Pharmaceuticals plc 17
DBV Technologies S.A. 18
HAL Allergy BV 19
Stallergenes S.A. 20
House Dust Mite Allergy-Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AllerDM-Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
allergenic pollen extract of timothy-Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BM-35-Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
House Dust Mite-SPIRE-Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MK-8237-Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PL-103-Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
S-524101-Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Viaskin House Dust Mite-Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
House Dust Mite Allergy-Recent Pipeline Updates 39
House Dust Mite Allergy-Dormant Projects 43
House Dust Mite Allergy-Discontinued Products 44
House Dust Mite Allergy-Product Development Milestones 45
Featured News & Press Releases 45
Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet 45
Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet 45
Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development 46
Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet 47
Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction 48
Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 49
Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment 50
Jun 19, 2013: ALK-Abello's New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy 51
Nov 14, 2012: DBV Technologies Launches Third Viaskin Program For Treatment Of House Dust Mites Allergy In Young Children 51
Oct 10, 2012: Merck Plans To Initiate Phase III Clinical Trial With HDM AIT In North America 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
